<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://novapharmanews.com/eu/news/ec-approves-itvisma-onasemnogene-sma-ages-2-plus</loc>
    <lastmod>2026-07-26T11:11:57.530Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-26T08:10:01.407Z</news:publication_date>
      <news:title>EC Approves Itvisma Gene Therapy for SMA 2+</news:title>
      <news:keywords>Itvisma, onasemnogene abeparvovec, Rare Diseases, Neurology</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://novapharmanews.com/eu/news/chmp-recommends-lyrokaul-lerodalcibep-cholesterol</loc>
    <lastmod>2026-07-26T10:51:59.944Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-26T08:10:00.104Z</news:publication_date>
      <news:title>CHMP Backs Lyrokaul Monthly PCSK9 Shot</news:title>
      <news:keywords>Lyrokaul, lerodalcibep, Cardiology, Metabolic Disorders</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://novapharmanews.com/eu/news/ec-approves-tepkinly-epcoritamab-r2-follicular-lymphoma</loc>
    <lastmod>2026-07-26T11:03:27.618Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-26T08:09:58.847Z</news:publication_date>
      <news:title>EC Approves TEPKINLY Plus R2 for Follicular Lymphoma</news:title>
      <news:keywords>TEPKINLY, epcoritamab, Oncology, Hematology</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://novapharmanews.com/eu/news/chmp-recommends-lynavoy-linerixibat-pbc-pruritus</loc>
    <lastmod>2026-07-26T12:16:37.686Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-26T08:09:57.507Z</news:publication_date>
      <news:title>CHMP Backs Lynavoy for PBC Itch</news:title>
      <news:keywords>Lynavoy, linerixibat, Hepatology, Rare Diseases</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://novapharmanews.com/eu/news/chmp-recommends-nezglyal-leriglitazone-cerebral-ald</loc>
    <lastmod>2026-07-26T12:51:45.303Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-26T08:09:55.931Z</news:publication_date>
      <news:title>CHMP Backs Nezglyal for Cerebral ALD in Boys</news:title>
      <news:keywords>Nezglyal, leriglitazone, Rare Diseases, Neurology</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://novapharmanews.com/apac/news/nmpa-accepts-everest-lerochol-pcsk9-bla-china</loc>
    <lastmod>2026-07-26T11:35:09.246Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-26T08:04:48.544Z</news:publication_date>
      <news:title>NMPA Accepts Everest LEROCHOL PCSK9 BLA</news:title>
      <news:keywords>LEROCHOL, lerodalcibep, Cardiology, Metabolic Disorders</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://novapharmanews.com/uploads/articles/nmpa-accepts-everest-lerochol-pcsk9-bla-china.webp</image:loc>
      <image:title>NMPA Accepts Everest LEROCHOL PCSK9 BLA</image:title>
    </image:image>
  </url>
  <url>
    <loc>https://novapharmanews.com/apac/news/nmpa-ind-kelun-harbour-skb575-hbm7575-asthma</loc>
    <lastmod>2026-07-26T08:05:00.760Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-26T08:04:45.532Z</news:publication_date>
      <news:title>NMPA Clears Kelun-Harbour Asthma Bispecific IND</news:title>
      <news:keywords>SKB575, HBM7575, Respiratory, Immunology</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://novapharmanews.com/uploads/articles/nmpa-ind-kelun-harbour-skb575-hbm7575-asthma.webp</image:loc>
      <image:title>NMPA Clears Kelun-Harbour Asthma Bispecific IND</image:title>
    </image:image>
  </url>
  <url>
    <loc>https://novapharmanews.com/apac/news/neuronata-r-retains-mfds-als-conditional-approval-korea</loc>
    <lastmod>2026-07-26T08:04:42.479Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-26T08:04:42.479Z</news:publication_date>
      <news:title>Neuronata-R Keeps Korea ALS Conditional Nod</news:title>
      <news:keywords>Neuronata-R, lenzumestrocel, Rare Diseases, Neurology</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://novapharmanews.com/uploads/articles/neuronata-r-retains-mfds-als-conditional-approval-korea.webp</image:loc>
      <image:title>Neuronata-R Keeps Korea ALS Conditional Nod</image:title>
    </image:image>
  </url>
  <url>
    <loc>https://novapharmanews.com/apac/news/orasis-beska-presbyopia-tga-nda-australia</loc>
    <lastmod>2026-07-26T08:04:39.707Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-26T08:04:39.707Z</news:publication_date>
      <news:title>Orasis Files BESKA Presbyopia NDA in Australia</news:title>
      <news:keywords>BESKA, pilocarpine, QLOSI, Ophthalmology</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://novapharmanews.com/uploads/articles/orasis-beska-presbyopia-tga-nda-australia.webp</image:loc>
      <image:title>Orasis Files BESKA Presbyopia NDA in Australia</image:title>
    </image:image>
  </url>
  <url>
    <loc>https://novapharmanews.com/apac/news/hansoh-ris-rez-artemis-008-os-win-sclc-china</loc>
    <lastmod>2026-07-26T15:32:40.241Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-26T08:04:36.290Z</news:publication_date>
      <news:title>Hansoh Ris-Rez Hits OS Goal in China SCLC Trial</news:title>
      <news:keywords>risvutatug rezetecan, HS-20093, Ris-Rez, Oncology, Lung Cancer</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://novapharmanews.com/uploads/articles/hansoh-ris-rez-artemis-008-os-win-sclc-china.webp</image:loc>
      <image:title>Hansoh Ris-Rez Hits OS Goal in China SCLC Trial</image:title>
    </image:image>
  </url>
  <url>
    <loc>https://novapharmanews.com/us/news/fda-fast-track-lundbeck-lu-ah69593-narcolepsy</loc>
    <lastmod>2026-07-26T15:00:51.318Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-26T07:48:54.147Z</news:publication_date>
      <news:title>FDA Fast Tracks Lundbeck Lu AH69593 for Narcolepsy</news:title>
      <news:keywords>Lu AH69593, Neurology, Sleep Disorders</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://novapharmanews.com/uploads/articles/fda-fast-track-lundbeck-lu-ah69593-narcolepsy.webp</image:loc>
      <image:title>FDA Fast Tracks Lundbeck Lu AH69593 for Narcolepsy</image:title>
    </image:image>
  </url>
  <url>
    <loc>https://novapharmanews.com/us/news/monopar-rolling-nda-alxn1840-wilson-disease</loc>
    <lastmod>2026-07-26T10:02:39.996Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-26T07:48:50.750Z</news:publication_date>
      <news:title>Monopar Starts Rolling NDA for ALXN1840 Wilson</news:title>
      <news:keywords>ALXN1840, tiomolibdate choline, Rare Diseases</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://novapharmanews.com/uploads/articles/monopar-rolling-nda-alxn1840-wilson-disease.webp</image:loc>
      <image:title>Monopar Starts Rolling NDA for ALXN1840 Wilson</image:title>
    </image:image>
  </url>
  <url>
    <loc>https://novapharmanews.com/us/news/accord-launches-osvyrti-jubereq-denosumab-biosimilars</loc>
    <lastmod>2026-07-26T10:44:40.757Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-26T07:48:47.488Z</news:publication_date>
      <news:title>Accord Launches OSVYRTI and JUBEREQ Biosimilars</news:title>
      <news:keywords>OSVYRTI, JUBEREQ, denosumab-desu, Bone Health, Oncology</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://novapharmanews.com/uploads/articles/accord-launches-osvyrti-jubereq-denosumab-biosimilars.webp</image:loc>
      <image:title>Accord Launches OSVYRTI and JUBEREQ Biosimilars</image:title>
    </image:image>
  </url>
  <url>
    <loc>https://novapharmanews.com/us/news/par-health-launches-first-janumet-xr-generic-us</loc>
    <lastmod>2026-07-26T10:44:42.793Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-26T07:48:44.541Z</news:publication_date>
      <news:title>Par Health Launches First Janumet XR Generic</news:title>
      <news:keywords>sitagliptin, metformin, Janumet XR, Diabetes, Metabolic Disorders</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://novapharmanews.com/uploads/articles/par-health-launches-first-janumet-xr-generic-us.webp</image:loc>
      <image:title>Par Health Launches First Janumet XR Generic</image:title>
    </image:image>
  </url>
  <url>
    <loc>https://novapharmanews.com/us/news/fda-approves-tylenol-with-naproxen-otc-combo</loc>
    <lastmod>2026-07-26T10:44:41.839Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-26T07:48:41.360Z</news:publication_date>
      <news:title>FDA Approves TYLENOL with Naproxen OTC Combo</news:title>
      <news:keywords>TYLENOL with Naproxen, acetaminophen, naproxen sodium, Pain Management</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://novapharmanews.com/uploads/articles/fda-approves-tylenol-with-naproxen-otc-combo.webp</image:loc>
      <image:title>FDA Approves TYLENOL with Naproxen OTC Combo</image:title>
    </image:image>
  </url>
  <url>
    <loc>https://novapharmanews.com/apac/news/nmpa-approves-orzeyful-oveporexton-narcolepsy-china</loc>
    <lastmod>2026-07-26T15:45:23.600Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-25T05:50:52.390Z</news:publication_date>
      <news:title>Orzeyful: NMPA Clears First OX2R Agonist for NT1</news:title>
      <news:keywords>oveporexton, Orzeyful, Sleep Disorders, Neurology</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://novapharmanews.com/eu/news/chmp-july-2026-meeting-highlights-twelve-medicines</loc>
    <lastmod>2026-07-26T15:00:01.890Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-24T17:16:34.206Z</news:publication_date>
      <news:title>CHMP July 2026: 12 New Medicines Recommended</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://novapharmanews.com/eu/news/european-commission-approves-wegovy-pill-oral-glp1</loc>
    <lastmod>2026-07-26T14:31:23.251Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-24T17:16:32.997Z</news:publication_date>
      <news:title>EC Approves Wegovy Pill, First Oral GLP-1 in EU</news:title>
      <news:keywords>Wegovy, semaglutide, Obesity, Metabolic Disorders</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://novapharmanews.com/eu/news/chmp-recommends-obicetrapib-ubeslo-evlarco-cholesterol</loc>
    <lastmod>2026-07-26T00:38:26.229Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-24T17:16:31.698Z</news:publication_date>
      <news:title>CHMP Backs Obicetrapib Ubeslo and Evlarco</news:title>
      <news:keywords>obicetrapib, Ubeslo, Evlarco, Cardiology, Metabolic Disorders</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://novapharmanews.com/eu/news/ema-recommends-icotyde-icotrokinra-plaque-psoriasis</loc>
    <lastmod>2026-07-26T15:13:54.786Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-24T17:16:30.528Z</news:publication_date>
      <news:title>EMA Backs Icotyde, First Oral IL-23R Psoriasis Drug</news:title>
      <news:keywords>Icotyde, icotrokinra, Dermatology, Immunology</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://novapharmanews.com/eu/news/ema-recommends-susvimo-ranibizumab-implant-namd</loc>
    <lastmod>2026-07-26T07:00:46.141Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-24T17:16:29.026Z</news:publication_date>
      <news:title>EMA Recommends Susvimo Implant for Wet AMD</news:title>
      <news:keywords>Susvimo, ranibizumab, Ophthalmology</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://novapharmanews.com/apac/news/telix-illuccix-japan-phase-3-enrollment-complete</loc>
    <lastmod>2026-07-25T20:30:27.014Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-24T16:30:31.671Z</news:publication_date>
      <news:title>Telix Completes Illuccix Japan Phase 3 Enrollment</news:title>
      <news:keywords>Illuccix, TLX591-Px, 68Ga-PSMA-11, Oncology, Prostate Cancer</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://novapharmanews.com/uploads/articles/telix-illuccix-japan-phase-3-enrollment-complete.webp</image:loc>
      <image:title>Telix Completes Illuccix Japan Phase 3 Enrollment</image:title>
    </image:image>
  </url>
  <url>
    <loc>https://novapharmanews.com/apac/news/nmpa-accepts-toripalimab-perioperative-nsclc-junshi</loc>
    <lastmod>2026-07-26T04:50:17.891Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-24T16:30:28.878Z</news:publication_date>
      <news:title>NMPA Accepts Toripalimab Perioperative NSCLC sNDA</news:title>
      <news:keywords>toripalimab, Oncology, Lung Cancer</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://novapharmanews.com/uploads/articles/nmpa-accepts-toripalimab-perioperative-nsclc-junshi.webp</image:loc>
      <image:title>NMPA Accepts Toripalimab Perioperative NSCLC sNDA</image:title>
    </image:image>
  </url>
  <url>
    <loc>https://novapharmanews.com/apac/news/nmpa-approves-iza-bren-escc-china-systimmune</loc>
    <lastmod>2026-07-25T21:18:45.741Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-24T16:30:25.790Z</news:publication_date>
      <news:title>NMPA Approves Iza-bren for ESCC in China</news:title>
      <news:keywords>iza-bren, izalontamab brengitecan, Oncology</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://novapharmanews.com/uploads/articles/nmpa-approves-iza-bren-escc-china-systimmune.webp</image:loc>
      <image:title>NMPA Approves Iza-bren for ESCC in China</image:title>
    </image:image>
  </url>
  <url>
    <loc>https://novapharmanews.com/apac/news/takeda-tak-003-india-first-dengue-vaccine-dcgi</loc>
    <lastmod>2026-07-25T20:46:32.890Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-24T16:30:22.931Z</news:publication_date>
      <news:title>Takeda TAK-003 Wins India Dengue Vaccine Nod</news:title>
      <news:keywords>TAK-003, Vaccines, Infectious Diseases</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://novapharmanews.com/uploads/articles/takeda-tak-003-india-first-dengue-vaccine-dcgi.webp</image:loc>
      <image:title>Takeda TAK-003 Wins India Dengue Vaccine Nod</image:title>
    </image:image>
  </url>
  <url>
    <loc>https://novapharmanews.com/apac/news/nmpa-approves-ciprocopan-pnh-china-haisco</loc>
    <lastmod>2026-07-26T14:56:08.280Z</lastmod>
    <news:news>
      <news:publication>
        <news:name>NovaPharmaNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-24T16:30:19.492Z</news:publication_date>
      <news:title>NMPA Approves Ciprocopan for PNH in China</news:title>
      <news:keywords>ciprocopan, HSK39297, Rare Diseases, Hematology</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://novapharmanews.com/uploads/articles/nmpa-approves-ciprocopan-pnh-china-haisco.webp</image:loc>
      <image:title>NMPA Approves Ciprocopan for PNH in China</image:title>
    </image:image>
  </url>
</urlset>